Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Ophthalmology
Published in: International Ophthalmology 1/2018

01-02-2018 | Original Paper

Intravitreal anti-VEGF treatment for subretinal neovascularisation secondary to type 2 idiopathic juxtafoveolar telangiectasia

Authors: Teresa Barth, Florian Zeman, Horst Helbig, Maria-Andreea Gamulescu

Published in: International Ophthalmology | Issue 1/2018

Login to get access

Abstract

Purpose

To assess the long-term outcome of patients with subretinal neovascular membrane (SRNVM) secondary to type 2 idiopathic juxtafoveolar telangiectasia (IJT) receiving intravitreal anti-VEGF (vascular endothelial growth factor) injections.

Methods

A total of 14 eyes of 12 patients treated with intravitreal anti-VEGF for SRNVM related to type 2 IJT were retrospectively assessed.

Results

Nine men and 3 women with a mean age of 66 years (SD 12, range 47–87 years) were diagnosed with IJT-related SRNVM. On average, 6.8 injections (SD 5.5, range 3–18) were given per eye. Ten eyes were treated with ranibizumab, 3 eyes with bevacizumab and 1 eye received both substances. The median follow-up after the last injection was 31 months (IQR: 18, 48). In 6 eyes, BCVA improved by 1–4 lines (mean Δ +2.0 lines), 1 eye remained stable and 7 eyes showed decline of vision by 1–5 lines (mean Δ −2.1 lines). The baseline central foveal thickness was significantly reduced from a mean of 323 (SD 87) to 266 µm (SD 71 µm) at the last follow-up visit (p = 0.001).

Conclusions

SRNVM development is a severe complication of type 2 IJT. Since the establishment of intravitreal anti-VEGF treatment laser coagulation and PDT have lost significance. Intravitreal anti-VEGF therapy seems to be safe and effective for the treatment of IJT-related SRNVM. Frequently multiple intravitreal injections are necessary for stabilisation.
Literature
1.
Gass JD, Blodi BA (1993) Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study. Ophthalmology 100:136–146CrossRef
2.
Engelbrecht NE, Aaberg TM, Sung J, Lewis ML (2002) Neovascular membranes associated with idiopathic juxtafoveolar telangiectasis. Arch Ophthalmol 120(3):320–324CrossRefPubMed
3.
Charbel Issa P, Gillies MC, Chew EY et al (2013) Macular telangiectasia type 2. Prog Retin Eye Res 34:49–77CrossRefPubMed
4.
Chhablani J, Mithal K, Rao H, Narayanan R (2014) Diagnosis of subretinal neovascularization associated with idiopathic juxtafoveal retinal telangiectasia: fluorescein angiography versus spectra-domain optical coherence tomography. Graefes Arch Clin Exp Ophthalmol 252:549–553CrossRefPubMed
5.
Toygar O, Guess MG, Youssef DS, Miller DM (2016) Long-term outcomes of intravitreal bevacizumab therapy for subretinal neovascularization secondary to idiopathic macular telangiectasia type 2. Retina 36(11):2150–2157CrossRefPubMed
6.
Mandal S, Venkatesh P, Abbas Z, Vohra R, Garg S (2007) Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia. Graefes Arch Clin Exp Ophthalmol 245(12):1825–1829CrossRefPubMed
7.
Potter MJ, Szabo SM, Chan EY, Morris AHC (2002) Photodynamic therapy of a subretinal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis. Am J Ophthalmol 133(1):149–151CrossRefPubMed
8.
Smithen LM, Spaide RF (2004) Photodynamic therapy and intravitreal triamcinolone for a subretinal neovascularization in bilateral idiopathic juxtafoveal telangiectasis. Am J Ophthalmol 138(5):884–885CrossRefPubMed
9.
Park DW, Schatz H, McDonald HR, Johnson RN (1997) Grid laser photocoagulation for macular edema in bilateral juxtafoveal telangiectasis. Ophthalmology 10:1838–1846CrossRef
10.
Shukla D, Singh J, Kolluru CM, Kim R, Namperumalsamy P (2004) Transpupillary thermotherapy for subfoveal neovascularization secondary to group 2A idiopathic juxtafoveolar telangiectasis. Am J Ophthalmol 138(1):147–149CrossRefPubMed
11.
Berger AS, McCuen BW II, Brown GC, Brownlow RL (2004) Surgical Removal of subfoveal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis. Am J Ophthalmol 137:812–819CrossRef
12.
Stuart A, Ford JA, Duckworth S, Jones C, Pereira A (2015) Anti-VEGF therapies in the treatment of choroidal neovascularisation secondary to on-age-related macular degeneration: a systematic review. BMJ Open 5:e00776CrossRef
13.
Jorge R, Costa RA, Calucci D, Scott IU (2007) Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Graefes Arch Clin Exp Ophthalmol 245(7):1045–1048CrossRefPubMed
14.
Konstantinidis L, Mantel I, Zografos L, Ambresin A (2009) Intravitreal ranibizumab as primary treatment for neovascular membrane associated with idiopathic juxtafoveal retinal telangiectasia. Graefes Arch Clin Exp Ophthalmol 247:1567–1569CrossRefPubMed
15.
Mavrakanas N, Mendrinos E, Pournaras CJ, Salzmann J (2009) Intravitreal ranibizumab and bevacizumab for bilateral subretinal neovascularization secondary to idiopathic juxtafoveal telangiectasia type 2A. Acta Ophthalmol 87(8):930–932CrossRefPubMed
16.
Narayanan R, Chhablani J, Sinha M et al (2012) Efficacy of anti-vascular endothelial growth factor therapy in subretinal neovascularization secondary to macular telangiectasia type 2. Retina 32(10):2001–2005CrossRefPubMed
17.
Roller AB, Folk JC, Patel NM et al (2011) Intravitreal bevacizumab for treatment of proliferative and nonproliferative type 2 idiopathic macular telangiectasia. Retina 31(9):1848–1855CrossRefPubMed
18.
Rishi P, Shroff D, Rishi E (2008) Combined photodynamic therapy and intravitreal ranibizumab as primary treatment for subretinal neovascular membrane (SRNVM) associated with type 2 idiopathic macular telangiectasia. Graefes Arch Clin Exp Ophthalmol 246(4):619–621CrossRefPubMed
19.
Charbel Issa P, Finger RP, Kruse K, Baumuller S, Scholl HPN, Holz FG (2011) Monthly ranibizumab for nonproliferative macular telangiectasia type 2: a 12-month prospective study. Am J Ophthalmol 151(5):876–886CrossRefPubMed
20.
Do DV, Bressler SB, Cassard SD et al (2014) Ranibizumab for macular telangiectasia type 2 in the absence of subretinal neovascularization. Retina 34(10):2063–2071CrossRefPubMed
21.
Kupitz EH, Heeren TFC, Holz FG, Charbel Issa P (2015) Poor long-term outcome of anti-vascular endothelial growth factor therapy in nonproliferative macular telangiectasia type 2. Retina 35(12):2619–2626CrossRefPubMed
22.
Kovach JL, Rosenfeld PJ (2009) Bevacizumab (avastin) therapy for idiopathic macular telangiectasia type II. Retina 29(1):27–32CrossRefPubMed
23.
Gamulescu M-A, Walter A, Sachs H, Helbig H (2008) Bevacizumab in the treatment of idiopathic macular telangiectasia. Graefes Arch Clin Exp Ophthalmol 246(8):1189–1193CrossRefPubMed
24.
Meyer-ter-Vehn T, Herzog S, Schargus M, Gobel W, Guthoff R (2013) Long-term course in type 2 idiopathic macular telangiectasia. Graefes Arch Clin Exp Ophthalmol 251(11):2513–2520CrossRefPubMed
25.
Veloso CE, Vianna RN, Pelayes DE, Nehemy MB (2013) Intravitreal bevacizumab for type 2 idiopathic macular telangiectasia. Ophthalmic Res 49(4):205–208CrossRefPubMed
26.
Kupitz EH, Heeren TF, Holz FG, Charbel Issa P (2015) Poor long-term outcome of anti-vascular endothelial growth factor therapy in nonproliferative macular telangiectasia type 2. Retina 35:2619–2626CrossRefPubMed
Metadata
Title
Intravitreal anti-VEGF treatment for subretinal neovascularisation secondary to type 2 idiopathic juxtafoveolar telangiectasia
Authors
Teresa Barth
Florian Zeman
Horst Helbig
Maria-Andreea Gamulescu
Publication date
01-02-2018
Publisher
Springer Netherlands
Published in
International Ophthalmology / Issue 1/2018
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI
https://doi.org/10.1007/s10792-017-0447-0

Other articles of this Issue 1/2018

International Ophthalmology 1/2018 Go to the issue

Original Paper

Comparison of anterior segment measurements with LenStar and Pentacam in patients with newly diagnosed glaucoma

Original Paper

Study of aqueous cytokines in patients with different patterns of diabetic macular edema based on optical coherence tomography

Erratum

Erratum to: Delayed spontaneous closure of postsurgical cyclodialysis cleft

Original Paper

Extended targeted retinal photocoagulation versus conventional pan-retinal photocoagulation for proliferative diabetic retinopathy in a randomized clinical trial

Original Paper

Treatment outcome in patients with presumed tubercular uveitis at a tertiary referral eye care centre in Singapore

Original Paper

Is there an association between glaucoma and capillaroscopy in patients with systemic sclerosis?